SP
Spero Therapeutics, Inc.
SPRO · NASDAQ
$1.17 -2.50% (-$0.03)
1M -4.88%
Market Cap $67.7M
P/E Ratio 9.18x
Div. Yield -
ROE 16.17%
Piotroski F-Score Moderate
6/9Valuation
99 /100
Cheap P/E 9.18x
EV/EBITDA 2.47x
P/S 1.58x
Growth
42 /100
Stable Rev. growth 7.06%
Book val. growth 8.06%
EPS growth N/A
Profitability
87 /100
Strong Gross margin 100.00%
Net margin 17.18%
Op. margin 14.02%
Quality
75 /100
Excellent ROIC 12.56%
ROE 16.17%
ROA 13.99%
Debt
100 /100
Low Debt/Equity 0.05x
Current ratio 6.12x
Net debt/EBITDA -6.33x
Stability
12 /100
Unstable Beta 1.48x
Rev. volatility 83.77%
EPS volatility 299.71%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about SPRO
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Esther Rajavelu
Employees
25
Headquarters
Cambridge
Upcoming events
12 NOV
Earnings
Upcoming earnings report